Dronedarone: Need to Perform a CV Outcome Safety Study
|
|
- Audrey Cox
- 5 years ago
- Views:
Transcription
1 Dronedarone: Need to Perform a CV Outcome Safety Study Gerald V. Naccarelli M.D. Consultant: Glaxo-Smith-Kline, Pfizer, Sanofi, Boehringer-Ingelheim, Daiichi-Sankyo, Bristol Myers Squibb, Otsuka, Janssen
2 Clinical Profiles for Amiodarone and Dronedarone Amiodarone Dronedarone Iodine moiety Yes No T ½ 53 days hours Blocks I Kr ; I Ks ; B 1 ; I Ca ; I to ; I Na Yes Yes Dosing Daily after loading bid with meals Food effect Yes Yes CYP4503A4 metabolism Yes Yes Inhibits tubular secretion of creatinine Yes Yes Increase QT but low TDP Yes Yes Efficacy in suppressing AF 65% 50% Efficacy in suppressing ventricular tachyarrhythmias Yes Not well studied Decreases CV hospitalization No Yes Warfarin interaction Yes No Pulmonary/thyroid toxicity Yes No Safety concerns in CHF SCD-HEFT NYHA III ANDROMEDA Wolbrette DL, et al. Vasc Health Risk Manag. 2010;(6):
3 Dronedarone: Clinical Trials DAFNE 1 EURIDIS/ ADONIS 2 ERATO 3 ATHENA 4 DIONYSOS 5 ANDROMEDA 6 Trial objective Dose finding study Effect of dronedarone on maintenance of sinus rhythm Effect of dronedarone in the control of mean 24-hour ventricular rate Evaluate the efficacy and safety of dronedarone in the prevention of CV hospitalization or all-cause death Investigate efficacy and safety of dronedarone versus amiodarone for the maintenance of sinus rhythm Evaluate the potential benefit of dronedarone on all cause death or hospitalization for worsening heart failure Patient population Patient status at baseline Number of patients Dronedarone Versus Primary endpoint Persistent AF In AF but eligible for AAD treatment and cardioversion Paroxysmal/ persistent AF In sinus rhythm Permanent AF In permanent AF Paroxysmal/ Persistent AF In sinus rhythm or AF but eligible for cardioversion Persistent AF In AF but eligible for AAD treatment and cardioversion Unstable recently decompensated CHF patients Time to first AF recurrence Both arms received standard therapy* Time to first AF/AFL recurrence Both arms received standard therapy* Change in mean ventricular rate measured by 24- hour Holter on Day 14 compared to baseline Both arms received standard therapy* CV hospitalization or all-cause mortality Amiodarone Treatment failure defined as recurrence of AF OR premature study drug discontinuation for intolerance or lack of efficacy N/A Death from any cause or hospitalization for worsening heart failure 1. Touboul P, et al. Eur Heart J. 2003;24: Singh BN, et al. N Engl J Med. 2007;357: Davy et al. Am Heart J. 2008;156:527.e1-527.e9. 4. Hohnloser SH, et al. N Engl J Med 2009;360: Le Heuzey JY et al. J Cardiovasc Electrophysiol Apr 6 Epub 6. Køber L, et al. N Engl J Med. 2008;358:
4 DAFNE Dronedarone 400 mg bid increased median days in NSR from 5.3 days on placebo to 59.9 days with AF; RR=0.45 ( ) *(P<.05) No benefit of higher doses with increased GI toxicity at 800 mg bid 400 bid 600 bid 800 bid N Median days/nsr * Time to AF recur (RR) 0.45 ( ) 0.95 ( ) 0.68 ( ) 22.6% discontinued drug due to GI adverse effects DAFNE = Dronedarone Atrial FibrillatioN study after Electrical Cardioversion Touboul et al. Eur Heart L 2003; 24:
5 Dronedarone: AF Trials ADONIS (American-Australian-African trial on DronedarONe In atrial fibrillation or flutter patients for the maintenance of Sinus rhythm) Dronedarone 400 mg BID vs. placebo Primary Endpoint: First AF/AFl recurrence (Dronedarone reduced AF; p=.0017) Prolonged time to first AF/AFL symptomatic recurrence (p=0.021) Median time to first AF 59 days for placebo vs. 158 days for dronedarone (RR=.725; CI = )(p=.0017) Rate during recurrence, 12 bpm slower (116.6 to bpm) on dronedarone (p<.001) EURIDIS (EURopean trial In atrial fibrillation or flutter patients receiving Dronedarone for the maintenance of Sinus rhythm) Dronedarone 400 mg BID vs. placebo Primary Endpoint: First AF/AFl recurrence (Dronedarone reduced AF by 22%; p=.0017) Prolonged time to first AF/AFL symptomatic recurrence (p=0.0055) Median time to first AF 41 days for placebo vs. 96 days for dronedarone (RR=.784; CI = ) (p=0.0138) Rate during recurrence, 15 bpm slower (117.5 to bpm) on dronedarone (p<.0001) Singh BN et al. NEJM 2007;357:
6 Cumulative Incidence Singh BN, et al. N Engl J Med 2008;358: EURIDIS / ADONIS: Effect on Death or CV Hospitalization (Post-Hoc Analysis) Trial Dronedarone Relative risk (95% CI) EURIDIS 35 / / ( ) ADONIS 29 / / ( ) Pooled 64 / / ( ) HR= 0.80 ( ) 400 mg BID 0.1 Number at risk: 400 mg BID Days
7 ANDROMEDA: Inclusion Criteria Recently hospitalized patients Having symptomatic heart failure (current NYHA class II-IV) with the following: At least 1 episode of decompensation corresponding to NYHA class III-IV within the last month WMI 1.2 (~LVEF 35%) These patients may have been clinically improved at the time of enrollment, and it is the history of decompensation that characterized them Patients were to be enrolled whether or not they had a history of atrial fibrillation or flutter; AF (if present) may have been long-standing or recent onset. WMI = wall motion index. MULTAQ [package insert], sanofi-aventis US LLC: Køber L et al. N Engl J Med. 2008;358: Kober L, et al. N Engl J Med 2008:358;
8 ANDROMEDA: Primary End Point Time to death or hospitalization for worsening HF (n=317) Dronedarone 400 mg BID (n=310) Patients reaching end point (n) RR % CI Log-rank s test result (p value) Kober L, et al. N Engl J Med 2008:358;
9 Cumulative Incidence ANDROMEDA: Mortality Results at Time of DSMB Recommendation 0.3 Drug # Events / # at Risk Relative Risk (95% CI) 12 / 317 Dronedarone 25 / ( ) 0.2 Mean duration of follow-up = 2 months 0.1 Dronedarone 0.0 At risk Days Following Randomization PBO DRO Kober L, et al. N Engl J Med 2008:358;
10 ANDROMEDA: Adjudicated Mode of Cardiovascular Death Dronedarone Cardiovascular death 9 24 Sudden death 6 10 Nonsudden death 3 14 Myocardial infarction 2 0 Worsening heart failure 2 10 Documented arrhythmia 2 6 Procedure related 0 1 Other cardiovascular 0 2 Presumed cardiovascular 3 5 No arrhythmia or sudden death was related to torsade de pointes
11 ANDROMEDA: Possible Explanations A chance finding related to the uncertainty associated with the frequent interim monitoring of small numbers of events in a trial that was terminated early. A true finding related to differences in the use of certain background medications following randomization. A true finding that can be explained by a deleterious effect of dronedarone in recently unstable patients who were hospitalized for decompensated heart failure and who did not have nonpermanent atrial fibrillation.
12 Cumulative Incidence (%) ATHENA: Primary Endpoint (CV Hospitalization or Death) 4628 patients with paroxysmal or persistent AF were randomized if they met the following: 75 years of age with or without additional risk factors or 70 years of age and 1 risk factor (HTN, diabetes, prior stroke/tia, LA diameter 50 mm, LVEF 0.40) 0 Dronedarone % reduction in relative risk Exclusion Criteria Permanent AF Unstable hemodynamic condition (ie, decompensated heart failure within HR previous = wk) NYHA class IV CHF P<.001 Bradycardia <50 bpm PR interval >280 msec Months ATHENA = A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation. Hohnloser SH, et al. N Engl J Med. 2009;360(7):
13 ATHENA Fatal Outcomes Outcome (n=2327) Dronedarone (n=2301) Hazard Ratio 95% CI P Value All deaths Non-CV deaths CV deaths Cardiac nonarrhythmic deaths Cardiac arrhythmic deaths Vascular noncardiac Hohnloser et al. N Engl J Med. 2009;360: (A).
14 Treatment Emergent Adverse Events in Randomized and Treated Patients 20 (N=2313) Dronedarone (N=2291) Patients with any TEAE 1603 (69%) 1649 (72%) Gastro-intestinal 508 (22%) 600 (26%) Respiratory 337 (15%) 332 (15%) Skin 176 (8%) 237 (10%) Creatinine increase 31 (1%) 108 (4.7%) Patients with any serious TEAE 489 (21%) 456 (20%) Gastro-intestinal 68 (3%) 81 (4%) Respiratory 45 (2%) 41 (2%) Skin 6 (0.3%) 7 (0.3%) Creatinine increase 1 (<0.1%) 5 (0.2%) Patients permanently discontinued study drug for any TEAE 187 (8%) 290 (13%)
15 Mortality Results of ATHENA Are Discordant With Those of ANDROMEDA ANDROMEDA Drug # Events / # at Risk Relative Risk (95% CI) 12 / Dronedarone 25 / 310 ( ) Drug ATHENA # Events / # at Risk Relative Risk (95% CI) 139 / Dronedarone 116 / 2301 ( )
16 Assessment of Risk: Subgroup Analysis of All-Cause Mortality in ATHENA LV ejection fraction NYHA Class Diuretics Betablockers ACE inhibitors Subgroup # Patients Relative risk (95% CI) Dronedarone: placebo < ( ) ( ) III ( ) I-II ( ) Yes ( ) No ( ) Yes ( ) No ( ) Yes ( ) No ( )
17 Was ATHENA a CV Outcome Study That Helped the Selection of Appropriate Patient for Dronedarone? Appropriate Patient Patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors (ie, age >70, hypertension, diabetes, prior cerebrovascular accident, left atrial diameter 50 mm or left ventricular ejection fraction [LVEF] <40%), who are in sinus rhythm or who will be cardioverted Dronedarone is an antiarrhythmic drug indicated to reduce the risk of cardiovascular hospitalization If heart failure develops or worsens, consider the suspension or discontinuation of Dronedarone Advise patients to consult a physician if they develop signs and symptoms of heart failure, such as weight gain, dependent edema, or increasing shortness of breath Inappropriate Patient Patients with NYHA class IV heart failure NYHA class II III heart failure with recent decompensation requiring hospitalization or referral to a specialized heart failure clinic This unstable population above corresponds to the population of the ANDROMEDA trial, in which patients receiving Dronedarone had a greater than 2-fold increase in mortality compared to placebo NYHA = New York Heart Association. MULTAQ [package insert], sanofi-aventis US LLC: 2009.
18 Post-Hoc ATHENA: Cardiovascular Hospitalization or Death in Permanent AF HR=0.67 p=0.069 On Treatment 17
19 PALLAS Permanent Atrial fibrillation outcome Study DRONEDARONE Screen Permanent AF 6m + CV risk No NYHA unstable III or IV NYHA CHF R 2 years, recruitment; 12 m min FU common end-date 10,800 patients; 844 events 90% power for 20% RRR and 2 sided alpha of 5% PLACEBO 1 0 Outcomes 1 st Co-primary (Stroke/MI/SEE/CV Death) 2 nd Co-primary (All Death/Unplanned CV Hospitalization) Dronedarone (n = 1619) (n = 1617) Dronedarone vs Events %/yr Events %/yr HR 95% CI P value <0.001 Connolly S. et al. N Engl J Med Nov 14. [Epub ahead of print]
20 PALLAS Trial: Baseline Demographics Patients with paroxysmal or persistent AF excluded Characteristic Dronedarone (N=1619) (N=1617) CAD 40.8% 41.2% Symptomatic HF 14.4% 14.8% LVEF 40% 21.3% 20.7% Previous Stroke or TIA 26.9% 28.3% PAD 11.6% 13.2% Age 75 + HTN and DM 18.2% 17.1% Permanent AF >2 years 69.1% 69.5% HF 68.4% 66.9% Class I 14.5% 12.9% Class II 45.2% 46.3% Class III 8.7% 7.7% Connolly, SJ et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011; DOI: /NEJMoa Published Nov 14, Accessed Nov 15, 2011.
21 Rate per 100 Patient-Years PALLAS Trial: Dronedarone in Permanent AF PALLAS enrolled 3236 patients 65 years with >6 month history of permanent AF and risk factors for major vascular events. The study was stopped for safety reasons. 30 P<.001 Dronedarone P< P = P = P =.049 P = Stroke, MI, Systemic Embolism, or CVD Death or Unplanned CV Hospitalization Death Stroke Hospitalization for HF Connolly, SJ et al.. N Engl J Med HF Episode or Hospitalization
22 ATHENA (Overall) vs PALLAS Risk Factors PALLAS Risk Factors ATHENA (Overall) Dronedarone n = 2301 % n = 2327 % Dronedarone (n = 1619) % PALLAS (n = 1617) % CAD Prior Stroke/TIA Symptomatic HF LVEF < 40% Peripheral Arterial Disease Age > 75 with HTN & Diabetes Hohnloser SH, et al. N Engl J Med. 2009;360: Connolly S. et al. N Engl J Med 2011 Dec 15;365(24):
23 Baseline characteristics Events Patient Populations and Outcomes in ATHENA, ANDROMEDA and PALLAS ATHENA PALLAS ANDROMEDA Type of AF Non-Permanent AF (75% in sinus rhythm at baseline) Permanent AF Not an AF Study (patients hospitalized for moderate to severe CHF) CHF Status (dronedarone arm) No CHF = 70.8% CHF I II = 25.2% CHF III = 4.3% No CHF = 30.9% CHF I II = 60.9% CHF III = 8.2% No CHF = 0% CHF I II = 42.3% CHF III IV =57.7% All deaths (D vs P) Stroke Outcome (D vs P) CHF Hospitalizations (D vs P) 5% vs 6% 1% vs 0.44% 8.1% vs 3.8% 1.2% vs.1.8% 1.1% vs 0.44% 1.3% v. 0.9%* 4.9% vs 5.7% 7.3% vs. 3.2% 9.8% v. 12.6% * 4 in D group vs 3 in P group
24 Reporting rate ( Nb of cases per 1000 patient-years**) Dronedarone Post-marketing Safety: What is Role of Post-Marketing Data? CCSI v3: liver failure added CCSI v5: ILD added PALLAS prematurate termination CCSI v July 2009 / 31 Jan Feb / 31 July 2010 PSUR=Periodic Safety Update Report (Number of patients exposure per PSUR period) 1 Aug / 31 Jan Feb / 31 July Aug / 31 Jan CCSI=Company Core Safety Information ILD=Interstitial Lung Disease 1 Feb / 31 July 2012 * SOC: System Organ Class **Exposure: patient- years calculation = (Nb tablets sold/ daily dose (2 tablets) / 365 days a year ***CSI: Company Safety Information HCP=Healthcare professional
25 Dronedarone AF Development Program: Lessons Learned Better dose ranging needed Patient selection important: SHD, CHF, Permanent AF Readjust further trials based on issues from early trials after discussion with FDA Clinical endpoints more important than surrogate endpoints Studies can be designed to assess CV safety as part of PI indication Some long-term safety can be assessed by keeping patients on study drug after trial is complete and there is a role for post-marketing studies
26 Summary Slide: Dronedarone What Was The CV Safety Issue Leading to Outcome Study Requirement Weight of Evidence Increased mortality in patients with NYHA class II III heart failure with recent decompensation Doubling of mortality in this population Presence of a Likely MOA for Risk Benefit:Risk Relationship for Drug? Is perceived risk: Generalizable to Other Drugs in Class or with Same Efficacy MOA? Lesions Learned Negative inotropy? No evidence of worsened mortality in ATHENA when above patients excluded from study Possible similar explanation to worsened mortality with amiodarone in SCD-HeFT in NYHA class III With antiarrhythmic drugs, patients populations matter for CV drug safety
Update on Dronedarone and Cardiovascular Outcomes
Update on and Cardiovascular Outcomes Dr. Stuart Connolly MD McMaster University Hamilton Ontario Disclosure: Research grants, speaker fees and consulting honoraria from sanofi aventis has key structural
More informationDronedarone For Atrial Fibrillation: Unbridled Enthusiasm Or Just Another Small Step Forward?
Dronedarone For Atrial Fibrillation: Unbridled Enthusiasm Or Just Another Small Step Forward? James A. Reiffel, M.D. Introduction In July 2009, the federal Food and Drug Administration (FDA) approved the
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationDronedarone in the Post-Pallas Era. Jorge E. Schliamser, MD Carmel Medical Center Haifa
Dronedarone in the Post-Pallas Era Jorge E. Schliamser, MD Carmel Medical Center Haifa Disclosures None Dronedarone is a multichannel blocker Dronedarone possesses electrophysiologic characteristics of
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationDebate PRO. Dronedarone is an important drug in the management of paroxysmal atrial fibrillation. John Camm
ESC ICM - Internationales Congress Center München 2012 Atrial Fibrillation Controversies in Medical Treatment Debate Dronedarone is an important drug in the management of paroxysmal atrial fibrillation
More informationPRESCRIBING ALERT
www.empr.com PRESCRIBING ALERT Dear Healthcare Professional, At MPR we strive to bring you important drug information in a concise and timely fashion. In keeping with this goal, we are pleased to bring
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationdronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd
dronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd 6 August 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationAF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?!
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! DRUG#PROPHYLAXIS#OF#AF:# FOCUS#ON#DRONEDARONE# Friday#16C10C2015# Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research
More informationAtrial Fibrillation 2009
Atrial Fibrillation 2009 Michael Glikson, MD Director of Pacing & Electrophysiology Leviev Heart Center Sheba medical Center Sheba Medical Center Tel Hashomer The Leviev Heart Center Rhythm vs rate control
More informationDronedarone for the treatment of non-permanent atrial fibrillation
Dronedarone for the treatment of non-permanent atrial Issued: August 2010 last modified: December 2012 guidance.nice.org.uk/ta197 NICE has accredited the process used by the Centre for Health Technology
More informationDronedarone( What%is%the%future?!
Dronedarone( What%is%the%future?! DRUG(PROPHYLAXIS(OF(AF:( FOCUS(ON(DRONEDARONE( Friday(16>10>2015( Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research grants, consulting
More informationNational Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007
Dronedarone (Multaq) for atrial fibrillation and atrial flutter December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationDronedarone: Where Does it Fit in the AF Therapeutic Armamentarium?
Dronedarone: Where Does it Fit in the AF Therapeutic Armamentarium? Abstract James A. Reiffel, M.D. Department of Medicine, Division of Cardiology, Columbia University Medical Center Dronedarone is a derivative
More informationSafety and Efficacy of Dronedarone in the Treatment of Atrial Fibrillation/Flutter
Clinical Medicine Insights: Cardiology Expert Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Safety and Efficacy of Dronedarone in the Treatment of
More informationATHENA - A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular
1 ATHENA - A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patients
More informationSaudi Heart Association February 22, 2011
Pharmacological Therapy of Atrial Fibrillation: Recent Advances Dr Martin Green Professor of Medicine (Cardiology) University of Ottawa Saudi Heart Association February 22, 2011 Atrial Fibrillation Drugs
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationStuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med
Stuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med None There s no reason to panic. While it is true that one of the crew members is ill, slightly. Absence of discrete P waves Chaotic
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationDronedarone and Atrial Fibrillation: A Critical Review
Clinical Medicine Reviews in Vascular Health Review Dronedarone and Atrial Fibrillation: A Critical Review David Singh 1, Eugenio Cingolani 2, Sanjay Kaul 2 and Steven Singh 3 1 University of California
More informationRelevant Advances in Atrial Fibrillation
Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisco Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Antiarrhythmic Drug
More informationDronedarone in patients with congestive heart failure: insights from ATHENA
European Heart Journal (2010) 31, 1717 1721 doi:10.1093/eurheartj/ehq113 CLINICAL RESEARCH Heart failure/cardiomyopathy Dronedarone in patients with congestive heart failure: insights from ATHENA Stefan
More informationAntiarrhythmic agents in 2014
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Antiarrhythmic agents in 2014 Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice, Italy
More informationGeriatric Grand Rounds
Geriatric Grand Rounds Tuesday, April 13, 21 12: noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More informationPALLAS. Dronedarone on Top of Standard Therapy. Stuart J. Connolly MD. on behalf of the PALLAS investigators
PALLAS Permanent Atrial FibriLLAtion Outcome Study using on Top of Standard Therapy Stuart J. Connolly MD on behalf of the PALLAS investigators http://clinicaltrials.gov Number: NCT01151137 1 Disclosure
More informationOut with the old, in with The 2010 Atrial Fibrillation Guidelines
Out with the old, in with The 2010 Atrial Fibrillation Guidelines Kseniya Chernushkin B.Sc.(Pharm.), VCH/PHC Pharmacy Resident Mary Elliot B.Sc.(Pharm.), VCH/PHC Pharmacy Resident March 22, 2011 Outline
More informationClinical Investigations
Clinical Investigations Effects of Dronedarone Started Rapidly After Amiodarone Discontinuation Address for correspondence: Laura Immordino, MD 100 E. Lancaster Avenue Wynnewood, PA 19096 laura.immordino@gmail.com
More informationPrimary Care Update in Medicine January 31 February 1, 2013 New Management Options for Patients with Atrial Fibrillation
Primary Care Update in Medicine January 31 February 1, 2013 New Management Options for Patients with Atrial Fibrillation Anne B. Curtis, MD, FACC, FHRS, FACP, FAHA Charles and Mary Bauer Professor, Chair,
More informationReviews. Benefit-Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation
Reviews Benefit-Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation Address for correspondence: Stefan H. Hohnloser, MD Department of Cardiology J.W. Goethe University Hospital
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationRole of Dronedarone in Atrial Fibrillation: More Questions Than Answers
Role of Dronedarone in Atrial Fibrillation: More Questions Than Answers Daniel E. Hilleman, Pharm.D., FCCP, and Aryan N. Mooss, M.D. Key Words: dronedarone, atrial fibrillation, sinus rhythm, hypertension,
More informationEffect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Effect of on Cardiovascular Events in Atrial Fibrillation Stefan H. Hohnloser, M.D., Harry J.G.M. Crijns, M.D., Martin van Eickels,
More informationSamer Nasr, M.D. Mount Lebanon Hospital.
Samer Nasr, M.D. Mount Lebanon Hospital. Lone atrial fibrillation: Younger than 60 years old. No clinical or echo evidence of cardiopulmonary disease. Favorable prognosis. Thromboembolism usually not
More informationSupplementary Online Content
Supplementary Online Content Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): a randomzied clinical
More informationDronedarone for the treatment of atrial fibrillation and atrial flutter
National Institute for Health and Clinical Excellence Dronedarone for the treatment of atrial fibrillation and atrial flutter Comment 1: the draft remit Appropriateness Sanofi-aventis Sanofi-aventis believe
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationDronedarone for the management of atrial fibrillation
Published 2 March 2011, doi:10.4414/smw.2011.13158 Cite this as: Dronedarone for the management of atrial fibrillation Roman Brenner, Etienne Delacrétaz Department of Cardiovascular Medicine, University
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationThe RealiseAF registry:
The RealiseAF registry: An International, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of AF patients initial results PG.Steg on behalf
More informationAmiodarone Prescribing and Monitoring: Back to the Future
Amiodarone Prescribing and Monitoring: Back to the Future Subha L. Varahan, MD, FHRS, CCDS Electrophysiologist Oklahoma Heart Hospital Oklahoma City, OK Friday, February, 8 th, 2019 Iodinated benzofuran
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationAntiarrhythmics for Atrial Fibrillation: Practical Implications of Latest Clinical Developments CME
Antiarrhythmics for Atrial Fibrillation: Practical Implications of Latest Clinical Developments CME A. John Camm, MD; Stuart J. Connolly, MD; Jean-Yves F. Le Heuzey, MD CME Released: 12/08/2011; Valid
More informationHow atrial fibrillation should be treated in the heart failure patient?
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 13/15 Ottobre 2016 How atrial fibrillation should be treated in the heart failure patient? Matteo Anselmino Dipartimento Scienze
More informationWho Gets Atrial Fibrilla9on..?
Birmingham October 20 th 2013 AFA Pa9ents Day Symptoma9c Atrial Fibrilla9on What therapies are available? GENERAL BACKGROUND Andrew Grace Papworth Hospital and University of Cambridge Consultant: Medtronic
More informationAtrial fibrillation and mortality: where is the missing link? Isabelle C Van Gelder University Medical Center Groningen
Atrial fibrillation and mortality: where is the missing link? Isabelle C Van Gelder The Netherlands Madrid Europace June 2011 Conflict of interests Research grants from Medtronic, SJM, Biotronik, Boston,
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationEtienne Aliot. University of Nancy - France
Etienne Aliot University of Nancy - France Disclosures Consulting fees : - Bayer, Boehringer Ingelheim,GSK, MedaPharma, Pfizer/BMS,Sanofi Aventis. - Biotronik,Medtronic,St Jude Medical. Electrical vs Pharmacological
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationThe implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease
The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationRebuttal. Jerónimo Farré MD 2010
Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationHalf Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital
Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More information5/5/2010. World incidence 720, 000 new cases / year. World prevalence 5.55 million AF prevalence increasing with aging of population
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology UK World incidence 720, 000 new cases / year World prevalence 5.55
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationRecent observations have focused attention on the PVs as a source of ectopic activity i determining i AF
Atrial Fibrillation in 2010 Panos Vardas Professor of Cardiology President of EHRA Atrial Fibrillation Pathophysiology of AF Triggers Recent observations have focused attention on the PVs as a source of
More informationThe Role of ACEI and ARBs in AF prevention
The Role of ACEI and ARBs in AF prevention Dr. Sameh Shaheen MD, FESC Prof. of cardiology Ain-Shams university Time course of atrial substrate remodeling in relation to the clinical appearance of AF and
More informationAtrial Fibrillation: Guidelines through clinical cases and 2010 updates
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology World incidence 720, 000 new cases / year World prevalence 5.5 million
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationNovel Anticoagulants : Bleeding and Bridging
Novel Anticoagulants : Bleeding and Bridging Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA, FRCP, MA Professor, Thomas Jefferson Medical School Director Atrial Fibrillation Research and Education The
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationDigoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD, PhD, FACC on behalf of the ARISTOTLE Investigators
More informationMohammad Zubaid, MB, ChB, FRCPC, FACC
Management and one year outcome of atrial fibrillation in Middle Eastern cohort enrolled in the observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Mohammad Zubaid, MB, ChB, FRCPC, FACC
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More informationDisclosures. Advances in Cardiac Electrophysiology. CVA Risk by Type of AF. Outline
Disclosures Advances in Cardiac Electrophysiology Research Grant: NIH KL2 RR2413 Honoraria (minor): Biotronik St. Jude Medical Advances in Internal Medicine UCSF Department of Medicine, School of Medicine
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationMihai Gheorghiade MD
Mihai Gheorghiade MD Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois On behalf of: Stephen J Greene MD; Javed Butler MD MPH MBA; Gerasimos Filippatos
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationBenjamin/Circ May 2008/p948/Fig A
1 2 Benjamin/Circ May 2008/p948/Fig A As shown here, data from the Framingham Heart Study have helped to establish an association between atrial fibrillation and excess mortality that is independent of
More informationMehta Hiren R et al. IRJP 2 (3) DRONEDARONE: A NEW MOLECULE FOR ATRIAL FIBRILLATION Patel Paresh B 1, Patel Kamlesh C 1, Mehta Hiren R 2 *
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN 2230 8407 Available online http://www.irjponline.com Review Article DRONEDARONE: A NEW MOLECULE FOR ATRIAL FIBRILLATION Patel Paresh B 1, Patel Kamlesh C
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationHypertension and Atrial Fibrillation in 2017
Boma Inn, Eldoret, 24th 25thFebruary 2017 Hypertension and Atrial Fibrillation in 2017 Dr Mzee Ngunga Consultant Cardiologist Aga Khan University Hospital, Nairobi Objectives 1. Understand the relationship
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationESC. Update of the ESC Guidelines on Medical Therapy. John Camm. ICM Internationales Congress Center München
ESC 2012 ICM Internationales Congress Center München Update on Consensus Statements on Management of Atrial Fibrillation European Heart Rhythm Association Update of the ESC Guidelines on Medical Therapy
More informationקוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן
קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן INTRODUCTION The prevalence of atrial fibrillation (AF) is approximately 1.5 2% of the general population The arrhythmia is associated: with
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationNew Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD
New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone
More informationAblation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation
Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation 25 October 2008 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Assistant Professor
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationAtrial fibrillation workshop: rate- versus rhythm-control
Atrial fibrillation workshop: rate- versus rhythm-control Rocky Mountain Internal Medicine Conference Nov, 2011 Dr F. Russell Quinn Cardiac Electrophysiologist, Foothills Medical Centre, Calgary Disclosures
More informationAtrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation
Atrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation ANIL K. BHANDARI, M.D, Director, Electrophysiology and EPS Fellowship Program Good Samaritan Hospital/ Harbor UCLA
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationResynchronization/Defibrillation
Resynchronization/Defibrillation for Ambulatory Heart Failure Trial Cardiac Resynchronization Therapy for Mild to Moderate Heart Failure George Wells University of Ottawa Heart Institute Department of
More informationEFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation
EFFECTIVE SHARED CARE AGREEMENT Dronedarone - For the treatment and management of atrial fibrillation Specialist details Patient identifier Name INTRODUCTION This shared care agreement outlines how the
More informationARCA biopharma. Investment Community Webcast: Top-line Data from GENETIC-AF Phase 2B Clinical Trial
ARCA biopharma Investment Community Webcast: Top-line Data from GENETIC-AF Phase 2B Clinical Trial February 26, 2018 Safe Harbor Statement This presentation contains "forward-looking statements" for purposes
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More information